Unique Aspects of Hypertrophic Cardiomyopathy in Children

Madeleine Townsend,Aamir Jeewa,Michael Khoury,Chentel Cunningham,Kristen George,Jennifer Conway
DOI: https://doi.org/10.1016/j.cjca.2024.01.013
IF: 6.614
2024-01-01
Canadian Journal of Cardiology
Abstract:Hypertrophic cardiomyopathy (HCM) is a primary heart muscle disease characterized by left ventricular hypertrophy that can be asymptomatic or with presentations that vary from left ventricular outflow tract obstruction, heart failure from diastolic dysfunction, arrhythmias, and/or sudden cardiac death. Children younger than 1 year of age tend to have worse outcomes and often have HCM secondary to inborn errors of metabolism or syndromes such as RASopathies. For children who survive or are diagnosed after 1 year of age, HCM outcomes are often favourable and similar to those seen in adults. This is because of sudden cardiac death risk stratification and medical and surgical innovations. Genetic testing and timely cardiac screening are paving the way for disease-modifying treatment as gene-specific therapies are being developed.
cardiac & cardiovascular systems
What problem does this paper attempt to address?